US · Healthcare

Intellia Therapeutics Inc (NTLA)

Biotechnology

Intellia Therapeutics Inc (NTLA) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-05-24, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for NTLA

P/E ratio

25.00

Intellia Therapeutics Inc (NTLA) — FAQ

What is NTLA's P/E ratio?

The price-to-earnings (P/E) ratio for Intellia Therapeutics Inc (NTLA) is 25.00 (data as of 2026-05-24).

Does Intellia Therapeutics Inc pay a dividend?

Dividend yield is not available in the current snapshot for Intellia Therapeutics Inc (NTLA). Check the MyAverix Finance app for the latest dividend data.

What sector is Intellia Therapeutics Inc in?

Intellia Therapeutics Inc (NTLA) is classified in the Healthcare sector (Biotechnology industry).

What exchange is NTLA listed on?

NTLA is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)